

## INDEX

- A8–35 amphipol, 45  
 AB model of toxins, 86–88  
 A $\beta$  peptide, 134–136, 236  
 ABC transporters, 138, 140, 164, 243, 306–313  
   ABC exporters, 316–318  
   medical significance, 140  
   membrane domains, 140  
   nucleotide-binding domains, 140  
   substrate-specific components, 140  
   TAP, 388  
 acetaminophen, 227  
 acetylcholine, 144–145, 294  
 acetylcholine esterase, 294  
 acetyl-coenzyme A, 14, 239  
 AcrA, 323  
 AcrAB/TolC tripartite drug efflux system, 320–325  
 AcrB, 321–323  
*Actinobacillus actinomycetemcomitans*, 325  
 active transport, 137–138  
 acyl chains, 1, 14–17  
   interdigitation, 27–28  
   torsion angle, 15  
   See also ABC transporters, ATPases, secondary transporters  
 acyltransferase, 85  
 adenylate cyclase, 325  
 adherins, 354  
 adhesion family of GPCRs, 259  
 ADP/ATP carrier (AAC), 143, 291–294  
 ADP-ribosylation factor, 83, 85  
 adrenaline (epinephrine), 258, 267  
 adrenergic receptors, 267–273  
   activated  $\beta_2$ AR in complex with Gs, 270–273  
    $\alpha$ -adrenergic receptors, 267  
    $\beta_1$ AR structure, 270  
    $\beta_2$ AR structure, 268  
    $\beta$ -adrenergic receptors, 264, 267–268  
 aerolysin, 88  
*Aeromonas*, 88  
*Aeropyrum pernix*, 335  
 Agre, Peter, 329  
 alamethicin, 88–90, 138  
 albuterol, 267  
 $\alpha$ -helical barrels  
   Wza, 126–127  
 $\alpha$ -helical membrane proteins  
   protein folding studies, 170–173  
 $\alpha$ -helices, 93–95, 102, 105, 138  
   See also helical bundles  
 alprenolol, 268  
 Alzheimer's disease, 236, 255  
   amyloid plaque formation, 134–136  
 AMBER program, 210  
 amino acid-polyamine-organocation (APC) family, 285, 303  
 amino acids symporters, 142  
 AMPA, 275, 278  
 amphetamine, 298  
 amphipathic  $\alpha$ -helix insertion  
   membrane binding, 83  
 amphiphile shape hypothesis, 29–30  
 amphiphilic molecules  
   hydrophobic effect, 4–5  
 amphiphysin, 84  
 amphipols, 45  
 amphitropic proteins, 70, 74  
 ampicillin, 321  
 amyloid beta (A $\beta$ ) peptide, 134–136, 236  
 amyloid precursor protein (APP), 134–135  
 anesthetics, 328  
 ankyrin, 71  
 annexin V, 85  
 annexins, 72–74  
 annulus, 9  
 anthrax toxin, 86–88, 117  
 anthrax vaccine, 86  
*anti* torsion angle, 15  
 antianxiety agents, 328  
 antibiotics, 90, 118  
 antibodies, 149  
 anticonvulsants, 298  
 antidepressants, 294, 298  
 antigens  
   translocation during immune response, 388  
 antimicrobial medicines, 90  
 antimicrobial peptides, 88  
 antiport  
   definition, 137  
 antiporters, 142–143, 294  
   GlpT, 288–289  
 APC (amino acid-polyamine-organocation) family, 285, 303  
 APC-fold superfamily, 300–303  
 Aph-1 (anterior pharynx defective-1), 135  
 apolipoprotein A-I, 66  
 apoptosis markers, 74  
 AQP fold, 330  
 AQP4 human aquaporin, 330, 333–335  
 aquaporins (AQP), 93, 117, 216, 329–335  
   AQP4 human aquaporin, 33, 35  
   GlpF glyceroaquaporin, 331–333  
   structure, 330–331  
*Aquifex aeolicus*, 294  
   LeuT, 296–300  
*Arabidopsis thaliana*, 255, 349  
 arabinose, 142  
 D-arabitol, 330  
 arachidic acid, 15  
 arachidonic acid, 15, 71, 227, 229, 230  
 Archaea, 116, 139, 140, 294, 335, 350  
   phospholipids, 20  
 archaeol, 20, 107  
 aromatic amino acids, 93  
 arrestins, 258, 267  
 arsenate, 139  
 aspartyl proteases, 235–236  
 aspirin, 227, 230  
 Astral compendium, 147  
 ATP-binding cassette transporters. See ABC transporters  
 ATP synthase, 106, 109  
 ATP synthesis, 106  
 ATPase superfamilies, 139  
 ATPases, 138  
   A-type, 139  
   F-type, 139  
   P-type, 139, 243–255  
     Ca<sup>2+</sup>-ATPases, 243–250  
     Cu<sup>+</sup>-ATPases, 255  
     H<sup>+</sup>-ATPases, 254–255  
     Na<sup>+</sup>, K<sup>+</sup>, ATPase, 250–254  
     SERCA, 243–250  
   V-type, 139, 294  
 atractyloside (ATR), 291  
 autism, 298  
 B factor, 220  
*Bacillus licheniformis*, 75  
 bacteria  
   ATP synthase, 139  
   chemotaxis, 386  
   fatty acids in membranes, 15–17  
   GlpG rhomboid protease, 237–239  
   group translocation of sugars, 140–142  
   MscL channels, 349  
   MscS channels, 350  
   OmpTins, 234  
   SecY translocon, 187  
   symporters, 142  
   virulence, 232, 234  
 bacteriochlorophyll (BChl), 112, 113, 114  
 bacteriocins, 232  
   colicins, 27  
 bacterio-opsin (bO), 173  
 bacteriopheophytin (BPh), 112

- bacteriorhodopsin (bR), 9, 45, 93, 94, 162, 163, 258  
 annular lipids, 215–216  
 crystal structure, 216  
 folding studies, 172–173  
 helical bundles, 105–109  
 nonannular lipids, 216  
 photocycle, 105–109  
 protein folding studies, 173–175  
 structure and functions, 105–109
- BAM complex, 191, 193
- Band 3 antiporter, 143
- BAR domains, 83–84
- bee venom, 88
- Benson–Green subunit model, 5–6
- benzyl-hydantoin transporter, 303
- $\beta$ -barrels, 93, 97, 102, 105, 115–126, 138  
 bioinformatics tools, 164–165  
 FadL (fatty acid transporter), 125  
 families of  $\beta$ -barrel proteins, 165  
 iron receptors, 125–126  
 membrane proteases, 234–235  
 NMR determination of structures, 119–121  
 OMPLA, 234  
 porins, 117–124  
 protein folding studies, 175–177  
 Tsx (nucleoside transporter), 124–125
- beta blockers, 267–268
- $\beta$ -lactams, 118, 321
- $\beta$ -strands, 105
- betaine, 298, 348
- betaine-choline-carnitine transporters (BCCT) family, 303–306
- BetP, 303  
 and osmoregulated transport, 303–306
- bicelles  
 model membrane systems, 63
- bile salts, 43, 321
- binding of ligands to surfaces, 80–81
- biogenic amine transporters, 294, 296
- bioinformatics  
 basics, 147  
 classification of membrane proteins, 130  
 database search tools, 147  
 databases of protein structural information, 147  
*E. coli* gene fusion approach, 149  
 Membrane Protein Explorer tool, 150
- bioinformatics tools, 146–165  
 $\beta$ -barrel prediction algorithms, 164–165  
 genomic analysis of membrane proteins, 153–161  
 helix–helix interactions, 162–163  
 hidden Markov models, 158–160  
 hydrophobicity plots, 148–149, 150, 151  
 hydrophobicity scales, 146–148
- inverted structural repeats, 151–153  
 orientation of membrane proteins, 149–150
- PHD neural networks algorithm, 156–158
- positive-inside rule for topology analysis, 150–151
- predicting TM segments, 146–148
- proteomics of membrane proteins, 163–164  
 statistical methods for TM prediction, 156–160
- biological hydrophobicity scale, 191–195
- Bip chaperone protein, 183
- bitopic proteins, 69–70, 91
- black films, 54
- BLAST program, 147
- Blastochloris viridis* (*Rhodospseudomonas viridis*), 109, 110–113
- blebs  
 model membrane systems, 64–65
- blisters  
 model membrane systems, 64–65
- blood groups, 17
- blood–brain barrier, 333
- BOCTOPUS algorithm, 165
- Bodipy-PC probe, 63
- bongkrekic acid (BA), 291
- Bordetella pertussis*, 325
- Borrelia burgdorferi*, 64
- botulinum neurotoxin, 86
- boundary layer of lipids, 9
- Boyer binding-change mechanism, 380
- Boyer, Paul, 376
- Bragg's law, 205–206
- brain tumors, 334
- BtuB, 125, 310, 313–315
- BtuCD–BtuF transporter, 310–313
- bucindolol, 270
- C1 binding domain, 74, 79–81
- C2 binding domain, 74, 79–81, 83
- C<sub>12</sub>E<sub>8</sub>, 50
- Ca<sup>2+</sup>-ATPases, 139, 243–250  
 ATP binding and hydrolysis, 247–249  
 Ca<sup>2+</sup> binding sites, 246–247  
 conformational changes, 249–250  
 cytoplasmic domains, 245  
 TM domains, 246
- Caenorhabditis elegans*, 144, 155, 278, 317
- CaiT, 303, 306
- calreticulin, 388
- cAMP, 75, 145, 258
- cancer, 227, 253  
 multidrug resistance, 140
- canine ER translocon, 187
- carazolol, 268, 270
- carbohydrate membrane constituents, 3
- carbon dioxide  
 removal from respiring cells, 143
- carboxyatractyloside (CATR), 292
- cardiolipin (CL), 19, 37, 38, 39, 112, 292, 293, 369
- cardiotonic steroids, 253
- cardiovascular disease, 253, 356
- carmoterol, 270
- carnitine, 143
- carotenoids, 112
- Carpet mechanism, 89
- carvedilol, 270
- cataracts, 356
- CATH database, 147
- caveolae, 36, 91
- caveolins, 36, 91, 354
- celecoxib (Celebrex), 227
- cell adhesion, 354
- cell division, 3
- cell motility, 354
- cellulases, 140
- ceramide, 76
- cerebrosides, 21
- cetyltrimethylammonium bromide (CTAB), 43
- channelopathies, 279, 328
- channels  
 aquaporins (AQP), 329–335  
 architecture, 329  
 chloride channels, 343–347  
 CLC family, 343–347  
 drug targets, 328  
 functions, 328  
 gap junction channels, 354–356  
 gating mechanisms, 328, 329  
 ion channels, 328  
 mechanisms, 329  
 mechanosensitive (MS) ion channels, 347–354  
 nature of the pores, 328  
 potassium channels, 335–343  
 selectivity mechanisms, 328
- chaperone proteins, 180–187
- CHAPS, 43, 46, 50, 61
- CHAPSO, 46, 63, 237
- CHARMM program, 210
- charybdotoxin, 335
- chemiosmotic theory, 106, 240, 359, 383
- chemotaxis in bacteria, 386
- chloride channels, 144, 343–347  
 as “broken” transporters, 346–347  
 ClC-ecl, 344–346
- chloroplasts, 116  
 $\beta$ -barrels, 165  
 membranes, 1  
 Toc75 system, 191
- CHOBIMALT, 46
- cholera, 316
- cholera toxin, 86
- cholesterol, 9, 21–22, 28, 34, 91, 132, 134  
 headgroup, 4  
 in detergent-resistant membranes (DRMs), 76

## Index

- in SLUVs, 62  
 interaction with GPCRs, 216  
 MD simulations, 213  
 role in amyloid formation, 136  
 solubility, 43  
 ternary phase diagrams, 31–34  
 choline, 294  
*cis* double bonds, 14  
 citrulline, 143  
 CL. *See* cardiolipin  
 clathrin, 84  
 CLC family, 343–347  
   chloride channels as “broken”  
   transporters, 346–347  
 ClC-ecl chloride channel, 344–346  
 CmCLC chloride channel, 346  
 coagulation, 74  
 cobra venom PLA<sub>2</sub>, 131–132  
 cocaine, 294, 298  
 colicin V, 325  
 colicins, 88, 138, 313, 316  
 complex formation  
   membrane research focus,  
   386–390  
 computer modeling, 203  
   molecular dynamics (MD), 209–213  
   Monte Carlo simulation, 213–214  
 congenital channelopathies, 279  
 congenital myasthenia, 145, 279  
 congestive heart failure, 139  
 connexins, 354–356  
 connexons, 354  
 CONPRED algorithm, 153  
*Corynebacterium glutamicum*, 303–306  
 cotranslational translocation, 180, 187  
 COX (cyclooxygenase), 227  
 COX-2 inhibitors, 230  
 COX site, 228, 229  
 creatine, 298  
 critical micellar concentration (CMC),  
   46, 47  
 critical micellar temperature (CMT),  
   46–47  
 crystallography of membrane proteins,  
   219–223  
 Crystodigin, 253  
 CT (cytidyltransferase), 83  
 CTAB (cetyltrimethylammonium  
   bromide), 43  
 CFTR. *See* cystic fibrosis transmembrane  
   conductance regulator  
 CTP (cytidine triphosphate), 83  
 Cu<sup>+</sup>-ATPases, 255  
 cubic phases of lipids, 30–31  
 curvature of membranes, 30, 83–84  
 CXCR4 chemokine receptor, 263  
*Cyanidioschyzon merolae*, 346  
 cyanocobalamin. *See* vitamin B<sub>12</sub>  
 cyanopindolol, 270  
 cyclic AMP, 75, 145, 258  
 cyclic GMP, 258  
 cyclodextrin, 21  
 β-cyclodextrin, 34, 36  
 cyclooxygenase (COX), 227  
 CYP27A, 137  
 CYP27B, 137  
 CYP3A4, 67  
 Cys-loop receptors, 278–281  
 Cys-loop superfamily, 144–145  
 cystic fibrosis, 200–201  
 cystic fibrosis transmembrane  
   conductance regulator (CFTR),  
   140, 316  
 cytidine triphosphate (CTP), 83  
 cytidyltransferase (CT), 83  
 cytochrome *b*, 240  
 cytochrome *b<sub>f</sub>*  
   structure and Q cycle, 368  
 cytochrome *bc<sub>1</sub>*, 70, 216, 365–370  
   high-resolution structures, 366–370  
   Q cycle, 366  
 cytochrome *bo<sub>3</sub>*, 164  
 cytochrome *c*, 70–71, 77–78  
 cytochrome *c* oxidase, 70–71, 162,  
   371–375  
   high-resolution structures, 371–373  
   oxygen reduction, 373–374  
   proton pathways, 374–375  
 cytochrome *c* peroxidase, 71  
 cytochrome P450 enzymes, 66, 132,  
   136–137  
 cytochrome P450 reductase (CPR), 67  
 cytoskeleton, 9–10, 64  
 Davson–Danielli–Robertson model, 5–6  
 DDM (dodecyl β-D-maltoside), 43, 46, 50,  
   96, 221  
 deafness, 289, 356  
 Debye–Hückel theory, 81  
 Debye–Waller factor, 220  
 Deisenhofer, Johann. *See* Michel,  
   Hartmut  
 dementia, 134  
 dental disease, 356  
 DEPC (dioleoyl phosphatidylcholine),  
   31, 212  
 depression, 294, 298  
 desipramine, 294  
 detergent-resistant membranes (DRMs),  
   35–37, 75, 76  
 detergents, 20, 43–51, 221  
   aggregation number (N), 48–49  
   critical micellar concentration (CMC),  
   46, 47  
   critical micellar temperature (CMT),  
   46–47  
   Krafft point, 46–47  
   lipid removal, 51  
   mechanisms of action, 46–49  
   membrane solubilization, 49–51  
   micelle formation, 46–49  
   types of, 43–46  
*dgkA* gene, 133  
 DHA (docosahexaenoic acid), 213  
 DHPC (dihexanoyl phosphatidylcholine),  
   97, 175  
 diabetes (type II), 143  
 diacylglycerol (DAG), 74, 76, 79, 85, 132  
 1,2-diacylglycerol, 258  
 diacylglycerol kinase (DAGK), 63,  
   132–133  
   protein folding studies, 177  
 dioleoyl phosphatidylcholine. *See*  
   DEPC  
 differential scanning calorimetry (DSC),  
   17, 77  
 diffraction techniques, 203  
   approaches to the lipid bilayer,  
   203–204  
   joint refinement of x-ray and neutron  
   diffraction data, 208  
   liquid crystal theory, 206–207  
   liquid crystallography, 204–206  
   neutron scattering, 205–206  
   x-ray scattering, 205–206  
 diffusion of bilayer lipids, 24–27  
 digitalis, 139  
 digitonin, 43  
 digitoxin, 253  
 digoxin, 253  
 dihexanoyl phosphatidylcholine (DHPC),  
   97, 175  
 DiI-C<sub>20</sub> fluorescent probe, 63  
 dilauroyl phosphatidylcholine. *See* DLPC  
 dimyristoyl phosphatidylcholine. *See*  
   DMPC  
 dimyristoyl phosphatidylethanolamine  
   (DMPE), 72  
 dimyristoyl phosphatidylglycerol  
   (DMPG), 63, 77  
 dimyristoyl phosphatidylserine (DMPS),  
   63, 77  
 dioleoyl phosphatidylcholine. *See* DOPC  
 dioleoyl phosphatidylethanolamine  
   (DOPE), 30  
 dioleoyl phosphatidylglycerol (DOPG), 78  
 DIP (Database of Interacting Proteins),  
   147  
 dipalmitoyl phosphatidylcholine. *See*  
   DPPC  
 dipalmitoyl phosphatidylethanolamine  
   (DPPE), 31  
 diphosphatidylglycerol, 19  
 diphtheria toxin (DT), 86, 138  
 distearoyl phosphatidylcholine. *See*  
   DSPC  
 disulfide bond oxidoreductases, 139  
 DLPC (dilauroyl phosphatidylcholine),  
   63, 102, 178  
 DM (decyl maltoside), 221  
 DMPC (dimyristoyl phosphatidylcholine),  
   24, 31, 63, 97, 102, 175, 213,  
   214, 237

- DMPE (dimyristoyl phosphatidylethanolamine), 72
- DMPG (dimyristoyl phosphatidylglycerol), 63, 77
- DMPS (dimyristoyl phosphatidylserine), 63, 77
- DNA polymerases, 37
- DNA synthesis, 37
- DnaA protein, 37, 83
- dobutamine, 270
- dodecyl  $\beta$ -D-maltoside. *See* DDM
- dodecyltrimethylamine oxide. *See* LDAO
- dodecylphosphocholine (DPC), 96, 121
- dolichols, 21
- dopamine, 91, 294
- dopamine D3 receptor, 263
- dopamine transporter, 298  
inhibitor, 294
- DOPC (dioleoyl phosphatidylcholine), 19, 30, 31–34, 175, 204, 208, 212
- DOPE (dioleoyl phosphatidylethanolamine), 30
- DOPG (dioleoyl phosphatidylglycerol), 78
- DPC (dodecylphosphocholine), 96, 121
- DPoPC (dipalmitoleoyl PC), 174
- DPPC (dipalmitoyl phosphatidylcholine), 31–34, 52, 63, 102, 176, 204, 211–213  
solubility, 43
- DPPE (dipalmitoyl phosphatidylethanolamine), 31
- DRMs. *See* detergent-resistant membranes
- Drosophila*, 236, 335
- drug efflux, 140
- drug efflux systems, 316–325  
AcrA, 323  
AcrAB/TolC tripartite drug efflux, 320–325  
AcrB, 321–323  
diverse mechanisms, 316  
EmrAB/TolC, 320  
EmrD, 289  
EmrE, 318–320  
HlyBD/TolC, 320  
membrane vacuum cleaner, 320–325  
multidrug resistance (MDR), 316, 320–325  
partners of TolC, 325  
P-glycoprotein, 316–318  
Sav1866, 316–318  
TolC, 320–325
- drug targets  
ion channels, 328  
neurotransmitter transporters, 294
- Dsb system, 191
- DSC (differential scanning calorimetry), 17, 77
- DSPC (distearoyl phosphatidylcholine), 31, 102
- dystonia with Parkinsonism, 254
- EAATs family, 294–296
- EF (edema factor), 86
- effector molecules, 257, 258
- EI (enzyme I), 140–142
- eicosanoids, 145
- elaidic acid, 14
- electron paramagnetic resonance (EPR), 99  
lipid miscibility studies, 31–33  
membrane protein–lipid interactions, 98–101  
myelin basic protein, 71
- electron spin resonance (ESR). *See* electron paramagnetic resonance (EPR)
- electron transfer  
redox loop, 240
- electron transport. *See* respiratory chain complexes
- electrophysiology, 54
- electrostatic interactions  
binding of peripheral proteins, 78–81  
myelin basic protein, 71
- electrostatic switch, 77
- ELIC, 279, 281
- embryonic development, 76
- EmrAB/TolC drug efflux system, 320
- EmrD, 289–290
- EmrE, 318–320
- endocytosis, 73, 76, 84, 91
- endophilin, 84
- endoplasmic reticulum (ER), 1, 21, 39, 102–103, 388
- endosomes, 86, 139
- energy transduction  
large molecular complexes, 358  
nitrate respiratory pathway, 358
- enterobactin (FepA), 125, 126
- EnvZ protein, 121
- epidermal growth factor (EGF), 36, 142
- epilepsy, 298, 334
- epinephrine, 258, 267
- epsin, 83
- ergosterol, 21
- Erwinia chrysanthemi*, 279
- erythrocytes  
aquaporin, 330  
Band 3 antiporter, 143  
effects of ankyrin deficiency, 71  
glucose transporter, 138  
glycophorin A, 94–95  
membrane lipid asymmetry, 27
- erythromycin, 321
- Escherichia coli*  
ABC transporters, 140  
AcrAB/TolC drug efflux system, 320  
AqpZ aquaporin, 330  
BAM complex, 191  
 $\beta$ -barrel proteins, 116, 165  
carnitine transporter (CaiT), 306  
chaperone proteins, 191
- CIC-ecl chloride channel, 344–346
- colicins, 88
- creation of GUVs, 62
- diacylglycerol kinase (DAGK), 132–133
- disulfide bond oxidoreductases, 139
- EmrD, 289
- EmrE, 318
- $F_1F_0$  ATP synthase, 376–377, 379
- FadL (fatty acid transporter), 125
- fatty acid proportions, 17
- FDH-N, 240–242
- FucP (fucose/H<sup>+</sup> symporter), 290–291
- functional analysis of inner membrane proteins, 163–164
- gene fusion technique, 149
- GlpF glycerol aquaporin, 330–333
- GlpG rhomboid protease, 237
- group translocation of sugars, 140–142
- iron receptors, 125
- lactose permease, 103, 142, 178
- lipid-anchored proteins, 75
- maltose transporter, 306–310
- mechanosensitive (MS) ion channels, 348–349, 350–351
- membrane blisters, 65
- membrane-derived oligosaccharides (MDOs), 132
- membrane fatty acids, 17
- membrane lipids polymorphism, 37–39
- OmpA, 121
- OMPLA, 232
- OmpT, 234
- OmpX adhesion protein, 119–121
- PEP PTS transport system, 140–142
- porins, 118, 121, 123, 124
- positive-inside rule for topology  
analysis, 150–151
- respiratory chain complexes, 359–365
- SecA and SecB, 183
- secondary transporters, 285
- structure of membrane proteins, 93
- symporters, 142
- TolC in tripartite drug efflux systems, 325
- translocon, 187, 189  
vitamin B<sub>12</sub> uptake system, 310–315
- ethidium bromide, 318, 320
- Eubacteria, 140
- eukaryotes  
cholesterol, 21  
cholesterol distribution in membranes, 27
- cytochrome P450 enzymes, 136–137
- membrane types, 1
- mitochondrial respiratory chain, 358–359
- Sec61 translocon, 187
- ExbB, 125
- ExbD, 125
- exocytosis, 3

## Index

- extrinsic proteins. *See* peripheral proteins
- F<sub>1</sub>F<sub>0</sub> ATP synthase (F<sub>1</sub>F<sub>0</sub> ATPase), 164, 239, 243, 379–380, 383  
catalytic mechanism of a rotary motor, 380  
F<sub>0</sub> domain, 379  
F<sub>1</sub> domain, 377–379  
regulation of the F<sub>1</sub>F<sub>0</sub>-ATPase, 379–380  
rotational catalysis, 380–383  
subunit structure and function, 377–379
- facial amphiphiles, 46
- FadL (fatty acid transporter), 125
- farnesyl group, 21
- FASTA program, 147
- fatty acid amide hydrolase, 91
- fatty acids  
*cis* double bonds, 14  
naming of, 14–15  
phase transitions, 17  
polyunsaturated, 15–17  
*trans* fatty acids, 14
- F-BAR domain, 83
- ferrichrome (FhuA), 125, 126
- ferrous ion, 112
- flingolimod, 270
- flap mechanism, 72, 77
- flavin, 136
- flip-flop TM process, 24, 25–27, 132
- flippases, 27
- flotation experiments, 204
- Fluid Mosaic Model, 3, 5–9, 24, 34  
historical development, 5–6
- fluidity of membranes  
measurement, 9
- fluorescence depolarization, 26
- fluorescence techniques, 27–26
- fluoxetine (Prozac), 294
- folding of membrane proteins, 91–92, 103  
*See also* protein folding studies
- formate dehydrogenase (FDH), 239–242, 358
- formoterol, 268
- fosfomicin, 288
- Fourier transforms, 205
- Franklin, Ben, 5
- FRAP (fluorescence recovery after photobleaching), 9, 24, 26, 31, 64
- FRET (fluorescence resonance energy transfer), 26, 76
- Frizzled/Taste2 family of GPCRs, 259
- fructose, 140
- Frye-Edidin experiment, 6
- FucP (fucose/H<sup>+</sup> symporter), 290–291
- fungi, 76
- FXFD proteins, 253
- FYVE binding domain, 81–83
- GABA ( $\gamma$ -aminobutyric acid), 294
- GABA transporter, 294, 298
- GABA<sub>A</sub> receptor, 279
- GABA<sub>C</sub> receptor, 279
- gain-of-function (GOF) mutations, 351–352
- galactitol, 164
- gangliosides, 21
- gap junction channels, 354–356  
medical significance, 356
- gated pores, 138
- gating mechanisms, 328, 329  
KcsA potassium channel, 337–339  
MS ion channels, 351–354  
potassium channels, 341, 339–343
- gauche* torsion angle, 15
- gel state, 17
- genetic studies  
*E. coli* membrane lipids  
polymorphism, 37–38
- genomic analysis of membrane proteins, 153–161
- geranylgeranyl group, 21
- giant unilamellar vesicles (GUVs), 62–63
- Gibbs absorption isotherm, 80–81
- GLIC, 279, 281
- Gloeobacter violaceus*, 279
- GlpF glyceroaquaporin, 330, 331–333
- GlpG rhomboid protease, 237–239
- GlpT antiporter, 288–289
- glpT* gene, 288
- GltPh aspartate transporter, 153, 294–296
- GluA glutamate receptors, 274
- glucagon, 258
- glucose, 140
- glucose-6-phosphate, 289
- glucose symporter, 142
- glucose transporter in erythrocytes, 138
- GluN glutamate receptors, 275
- GluR glutamate receptors, 275
- glutamate family of GPCRs, 259
- glutamate receptors  
GluA2, 274–278  
GluCl, 278–281
- glutamate symporter, 142
- glutamate transporters  
GltPh, 153, 294–296
- glutamine, 164
- glyceroaquaporins, 329–330  
GlpF, 331–333  
structure, 330–331
- glycerol, 19, 108
- glycerol facilitator, 93
- glycerol-2-phosphate, 288
- glycerol-3-phosphate (G3P), 19, 288, 289
- glycerophospholipids. *See* phospholipids (PL)
- glycine receptor, 279
- glycine transporter, 298
- glycolipids, 17–19
- glycophorin, 162, 163
- glycophorin A, 94–95, 97
- glycosphingolipids, 17–19
- glycosyl transferases, 76
- glycosylphosphatidylinositol (GPI), 74, 76–77
- GM<sub>2</sub> ganglioside, 17–19
- Goldman–Engelman–Steitz (GES) scale, 148, 155
- Golgi apparatus, 1, 39, 91, 102, 139  
protein trafficking, 36
- gonorrhoea, 316
- Gouy–Chapman theory, 81
- GPI-anchored proteins, 74, 76–77
- GPI-linked proteins, 36
- G protein complex, 258–259, 267, 270, 272–273
- G protein-coupled receptors (GPCRs), 66, 93, 145, 216, 257–258  
rhodopsin, 259–266  
rhodopsin as GPCR prototype, 263–266
- G proteins, 258–259, 267, 270, 272–273
- G protein-sensitive Kir3.2 (GIRK2) channel, 336
- gramicidin, 39, 52, 88, 90, 97, 102, 138
- gramicidin A, 90
- Gram-negative bacteria  
AcrAB/TolC drug efflux system, 320  
 $\beta$ -barrel proteins, 116, 165  
cell envelope structure, 116  
cell membrane arrangements, 1  
OMPLA, 230, 232  
periplasmic binding domains, 140  
porins, 9, 117  
TonB family of proteins, 138  
*See also Escherichia coli*
- Gram-positive bacteria, 116  
 $\beta$ -barrels, 165  
cell membrane arrangements, 1  
undecaprenol kinase (UDPK), 133
- greasy slide pathway, 124
- GROMOS program, 210
- Grotthuss mechanism, 333
- group translocation of sugars, 140–142
- G<sub>s</sub> protein complex, 85
- guanosine triphosphate (GTP), 85
- gustatory receptors, 145
- GxxxA amino acid sequence, 94, 162
- GxxxG amino acid sequence, 94, 161, 162
- H<sup>+</sup>-ATPases, 254–255
- Haemophilus influenzae*, 237
- Halobacter salinarum*, 105–109
- halobacteria, 9
- halorhodopsin, 162
- HasA protein, 126
- HasR protein, 126
- helical bundles, 93–95, 105–115  
bacteriorhodopsin (BR), 105–109  
helix–helix interactions, 162–163  
photosynthetic reaction center, 109–115

- helix–helix interactions, 162–163
- heme-binding protein, 126
- heme-dependent peroxidases  
superfamily, 229
- hemifluorinated surfactants, 45
- hemolysin, 316, 320, 325
- $\alpha$ -hemolysin ( $\alpha$ HL), 86
- hepatocytes, 102–103
- hexagonal phase of lipids, 29–30
- HHDBT (5-*n*-heptyl-6-hydroxy-4,  
7-dioxobenzothiazole), 370
- hidden Markov models, 153, 158–160,  
164, 165
- histamine H<sub>1</sub> receptor, 263
- HlyBD/TolC drug efflux system, 320
- HMMTOP algorithm, 153, 154, 158–160
- holins, 138
- hop diffusion, 25
- HOQNO (2-heptyl-4-hydroxyquinoline-*N*-  
oxide), 240
- hormones, 145
- HPr (histidine-containing phosphocarrier  
protein), 140–142
- Huber, Robert, 109
- human adenosine A<sub>2A</sub> receptor, 263
- human membrane proteome, 390
- humans  
ABC transporters, 140  
channelopathies, 328  
connexin isoforms, 354  
cytochrome P450 genes, 137  
genes for ion channels, 328  
glutamate transporters, 294–296  
GPCRs, 145  
immune response, 388–389  
medical significance of ABC  
transporters, 140  
membrane proteome, 390  
mitochondrial carriers, 143  
potassium channels, 341–343
- hydrogen bonding  
integral membrane proteins, 93  
interhelical, 163  
sphingolipids, 21  
in TM segments, 92  
water, 4–5
- hydrogenation of fatty acids, 14
- hydropathy plots. *See* hydrophobicity  
plots
- hydrophobic effect, 3  
and membrane formation, 4–5
- hydrophobic interactions  
binding of peripheral proteins,  
78–79, 81
- hydrophobic mismatch, 101–103
- hydrophobicity  
biological hydrophobicity scale,  
191–195  
whole protein hydrophobicity scale,  
178
- hydrophobicity plots, 148–149, 151, 155
- making and testing, 150
- hydrophobicity scales, 146–148
- hyperekplexia, 279
- hyperglycerolemia, 289
- I-BAR domain, 83
- ibuprofen, 227
- ICI-118,551, 268
- I-CLiPs (intramembrane-cleaving  
proteases), 235–236
- IGluRs (ionotropic glutamate receptors),  
274
- Ilyobactor tartaricus*, 379
- imipramine, 294
- immune response, 388
- immune system, 74, 88, 140
- inflammation, 227  
suppressors, 74  
triggers, 71
- influenza virus, 36
- innexins, 354
- inositol 1,4,5-triphosphate, 258
- insulin receptor, 144
- integral membrane proteins, 1, 6, 69–70,  
91–95  
amphipathicity, 6  
 $\beta$ -barrels, 115–126  
bitopic proteins, 91  
classes of, 105  
classification, 91  
folding, 91–92  
genomic analysis, 153–161  
helical bundles, 105–115  
orientation of membrane proteins,  
149–150  
polytopic proteins, 91  
predicting TM segments, 146–148  
proteomics, 163–164  
structures. *See* bioinformatics tools  
Wza ( $\alpha$ -helical barrel), 126–127
- interdigitation of acyl chains, 27–28
- INTERFACE-3 program, 162
- intracellular transport, 1
- intramembrane proteases, 134–136,  
235–236
- intrinsic curvature of membranes, 30
- intrinsic proteins. *See* integral membrane  
proteins
- inward-rectifying channels, 335
- iodocyanopindolol, 270
- ion channels, 143–144, 258  
channelopathies, 328  
drug targets, 328  
*See also* channels
- ion exchange chromatography  
cytochrome *c*, 70
- ionophores, 88–89, 138
- ionotropic receptors, 274
- iron receptors, 125–126
- isocoumarins, 236
- isoleucine, 95
- isoprenaline, 270
- isoprene, 15, 21, 75
- isoprenoids, 17–19, 21–22
- isoproterenol, 268
- isozymes, 132
- ivermectin, 279, 281
- juvenile myoclonic epilepsy, 279
- K2P family, 341–343
- kainate, 275
- KcsA potassium channel, 177–178, 275,  
329, 335–339  
gating and activation, 337–339  
selectivity, 336–337  
structural studies, 335–336  
structure, 336–337
- kinetic model for surface dilution,  
131–132
- Kir2.2 channel, 336
- Kirbac channel, 336
- knobs-into-holes structures, 95, 172, 232
- Kobilka, Brian, 258
- Krafft point, 46–47
- Krebs cycle, 143
- Kv channels, 335
- KvAP potassium channel, 335–336
- Kyte–Doolittle algorithm, 149
- L <sub>$\alpha$</sub>  state, 28–29, 31–34
- lactose permease (LacY protein), 61–62,  
103, 138, 142, 152–153, 178, 219,  
285–287
- lacY* gene, 285
- LacY protein. *See* lactose permease
- LamB (maltooporin), 117, 121, 123, 124
- lamellar phase of lipids, 28–29
- Langmuir isotherm, 80
- Langmuir trough, 52
- Lanoxin, 253
- large unilamellar vesicles (LUVs),  
61–62
- lateral diffusion of bilayer lipids, 24–27
- lateral domains, 34–35
- lauric acid, 15
- lauryldimethylamine oxide. *See* LDAO
- L <sub>$\beta$</sub>  state, 28–29, 31–34
- L<sub>C</sub> (liquid condensed) state, 52
- L<sub>c</sub> state, 28–29
- L<sub>d</sub> state, 31–34
- LDAO (lauryldimethylamine oxide), 43,  
96, 112, 221
- L<sub>E</sub> (liquid expanded) state, 52
- lecithin, 62
- Lefkowitz, Robert, 258
- Legionella pneumophila*, 255
- Lep (leader peptidase), 150–151, 191
- leukotoxins, 325
- leukotrienes, 71
- LeuT, 294, 296–300  
binding sites, 300

## Index

- inhibitors, 300
  - structures, 298–300
  - transport mechanism, 300
- LeuT superfamily, 285, 300–303
- LF (lethal factor), 86
- LGIC database, 145
- ligand binding to surfaces, 80–81
- ligand-gated ion channel (LGIC)
  - superfamily, 145
- ligand-gated ion channels, 257–258, 274
- ligands, 257
- light-induced signal transduction
  - efficiency, 260
- lignoceric acid, 15
- line tension, 35
- linear isoprenoids, 17–19, 21–22
- linoleic acid, 15
- $\alpha$ -linolenic acid, 15
- lipid-anchored proteins, 1, 75–77
- lipid asymmetry
  - and membrane thickness, 27–28
- lipid bilayer, 1–3
  - leaflets, 6
- lipid bilayer matrix, 22
  - curvature, 30–31
  - diffusion of bilayer lipids, 24–27
  - flip-flop process, 24, 25–27
  - lateral diffusion of bilayer lipids, 24–27
  - line tension, 35
  - lipid asymmetry and membrane thickness, 27–28
  - rotational diffusion of bilayer lipids, 24
  - structure of bilayer lipids, 22–24
  - transverse diffusion of bilayer lipids, 24, 25–27
- lipid diversity
  - acyl chains, 14–17
  - classes found in biomembranes, 17–19
  - composition and function of membranes, 37–39
  - isoprenoids, 21–22
  - linear isoprenoids, 21–22
  - phospholipids (PL), 19–20
  - sphingolipids, 20–21
  - sterols, 21–22
- lipid polymorphism, 28
  - amphiphile shape hypothesis, 29–30
  - cubic phases, 30–31
  - hexagonal phase, 29
  - lamellar phase, 28–29
  - miscibility of bilayer lipids, 31–33
  - phase diagrams, 31–34
- lipid–protein interactions, 6
- lipid rafts, 34–35, 76–77, 102, 354
  - detergent-resistant membranes (DRMs), 35–37, 75, 76
  - raft proteins, 36
  - role in amyloid formation, 135, 136
  - See also* membrane rafts
- lipid trafficking, 73
- lipids
  - amphiphilicity, 4–5
  - boundary layer, 9
  - definition, 4
  - headgroups, 4
  - in x-ray structures of membrane proteins, 215–216
  - melting temperature ( $T_m$ ), 17
  - naming of fatty acids, 14–15
  - phase transitions, 17
  - polyunsaturated fatty acids, 15–17
  - trans* fatty acids, 14
- lipopolysaccharide (LPS), 235
- liposomes, 124
  - giant unilamellar vesicles (GUVs), 62–63
  - kinetic model of surface dilution, 131
  - large unilamellar vesicles (LUVs), 61–62
  - model membrane systems, 60–63
  - multilamellar vesicles (MLVs), 60–61
  - proteoliposomes, 60, 61–62
  - short-chain/long-chain unilamellar vesicles (SLUVs), 62
  - small unilamellar vesicles (SUVs), 61
- liquid crystal theory, 206–207
- liquid crystalline state, 17
- liquid crystallography, 204–206
- LMPC (lyso-myristoyl phosphatidyl choline), 96
- $L_o$  state, 31–34, 35–37
- loss-of-function (LOF) mutations, 351–352
- lungs
  - myelin networks, 39
  - pulmonary surfactant, 52
- lysophospholipids, 20, 46
- lysosomes, 139
  - membranes, 1
- M1 matrix protein, 36
- M2 viral ion channel, 97
- MacKinnon, Roderick, 329
- major facilitator superfamily (MFS), 138, 284–291, 316
  - paradigm for MFS transporters, 291
- malaria, 334
- MalK protein, 140
- maltodextrins, 124
- maltoporin (LamB protein), 124
- maltose, 164
- maltose neopentyl glycol (MNG)
  - amphiphiles, 46
- maltose neopentyl glycol (MNG-3), 272
- maltose transporter, 140, 306–310
- maltotriose, 124
- mannose, 140, 164
- marine organisms
  - fatty acid proportions, 17
- mass spectrometry imaging, 9
- MATE (multidrug and toxic compound extrusion) family, 316
- mechanosensitive (MS) ion channels, 347–354
  - MS channel gating, 351–354
  - McsK channel, 348–349
  - MscL channels, 349–350
  - McsM channel, 348–349
  - MscS channels, 350–351
- mechanosensitivity, 349
- melibiose, 142
- melittin, 39, 88, 89
- melting temperature ( $T_m$ ), 29
  - effects of protein binding on membrane lipids, 77–78
  - fatty acids, 17
- membrane asymmetry, 9
- membrane binding
  - amphipathic  $\alpha$ -helix insertion, 83
- membrane binding domains, 81–83
  - C1, 74, 79–81
  - C2, 74, 79–81
  - FYVE, 81–83
  - pleckstrin homology (PH) domain, 81–83
- membrane biochips, 90
- membrane components
  - purification challenges, 42–43
  - purification process, 43
- membrane curvature
  - control of, 30
  - effects on folding, 175, 178
- membrane-derived oligosaccharides (MDOs), 132
- membrane enzymes, 130–137, 226–227
  - aspartyl proteases, 235–236
  - $Ca^{2+}$ -ATPases, 243–250
  - $\beta$ -barrel proteases, 234–235
  - cytochrome P450 enzymes, 132, 136–137
  - diacylglycerol kinase (DAGK), 132–133
  - formate dehydrogenase, 239–242
  - I-CLiPs (intramembrane-cleaving proteases), 235–236
  - intramembrane proteases, 134–136, 235–236
  - isoforms (isozymes), 132
  - lipid-dependent enzymes, 131–132
  - metalloproteases, 235–236
  - $Na^+$ ,  $K^+$  ATPase, 250–254
  - OMPLA (outer membrane phospholipase A), 230–234
  - Omptins, 234–235
  - presenilin, 134–136
  - prostaglandin  $H_2$  synthase (PGHS), 227–230
  - proteases, 234–239
  - P-type ATPases, 243–255
  - rhomboid proteases, 236–239
  - serine proteases, 235–236
  - surface dilution effects, 131–132
  - undecaprenol kinase (UDPK), 133
- membrane formation
  - hydrophobic effect, 4–5

- membrane functions
- dynamic protein complexes, 9–11
- membrane fusion systems, 387–388
- membrane protein biogenesis, 168, 178–201
- biological hydrophobicity scale, 191–195
- cleavable signal sequences involved in translocation, 180–187
- export from the cytoplasm, 180–187
- misfolding diseases, 198–201
- protein folding studies, 168–178
- threading into the translocon, 187
- through the translocon to the bilayer, 184
- TM insertion, 168–169, 189–191, 193–195
- topogenesis, 195–198
- translocon, 179, 187
- use of cross-linking to trace translocation, 184–185
- Membrane Protein Explorer tool, 150
- membrane proteins
- classification using bioinformatics data, 130
  - high-resolution structures, 226–227. *See also* numerous examples
  - multidisciplinary approach to investigation, 223
  - traditional functional descriptions, 130
- membrane rafts, 4, 9
- See also* lipid rafts
- membrane receptors, 144–145
- adrenergic receptors, 267–273
  - binding of signaling molecules (ligands), 257
  - classification, 257–258
  - G protein-coupled receptors (GPCRs), 145, 257–273
  - ionotropic type, 257–258
  - ligand-gated ion channels, 257–258
  - metabotropic type, 257–258
  - neurotransmitter receptors, 274–281
  - nicotinic acetylcholine receptor (nAChR), 144–145
  - rhodopsin, 259–266
  - signaling functions, 257
- membrane research
- achievement of high-resolution structures, 385
  - challenge of more complex proteins, 385
  - complex formation, 386–390
  - conformational changes and dynamics, 390
  - human membrane proteome, 390
  - membrane structural insights, 12
  - multidisciplinary approach, 390
- membrane scaffold protein (MSP), 66
- membrane-selective targeting, 85
- membrane solubilization, 49–51
- membrane structure
- dynamic protein complexes, 9–11
  - Fluid Mosaic Model, 5–9
  - lateral domains, 34–35
  - lipid rafts, 34–35
  - rafts, 9
  - variations in membrane composition, 7–9
- membrane thickness
- and lipid asymmetry, 27–28
- membrane transport proteins, 137–144
- ABC transporter superfamily, 140
  - active transport, 137–138
  - antiporters, 142–143
  - ATPase superfamilies, 139
  - definition of antiport, 137
  - definition of symport, 137
  - definition of uniport, 137
  - gated pores, 138
  - group translocation, 140–142
  - inverted structural repeats, 151–153
  - ion channels, 143–144
  - passive transport, 137–138
  - symporters, 142
  - transport classification system, 138–139
  - See also* transport proteins
- MEMSAT algorithm, 154, 153
- menaquinol (MQH<sub>2</sub>), 239, 240
- menaquinone (MQ), 112, 239
- Menkes' disease, 255
- metabotropic receptors, 274
- metalloproteases, 235–236
- Methanobacterium thermoautotrophicum*, 335, 338
- Methanocaldococcus jannaschii*, 236
- Methanococcus jannaschii*
- translocon, 187–190
- metoprolol, 267
- MexA, 323
- MexAB/OprM system, 323
- MHC1 peptide loading complex, 388
- Mhp1, 303
- micelles
- aggregation number (N), 48–49
  - critical micellar concentration (CMC), 46, 47
  - critical micellar temperature (CMT), 46–47
  - formation by detergents, 46–49
  - kinetic model for surface dilution, 131–132
  - Krafft point, 46–47
  - model membrane systems, 63
  - use in solving DAGK structure, 132
- Michaelis–Menten equation, 130
- Michaelis–Menten kinetics, 132
- Michel, Hartmut, 109
- migraines, 254
- miscibility of bilayer lipids, 31–33
- phase diagrams, 31–34
- Mitchell, Peter, 359
- mitochondria
- ADP/ATP carrier (AAC), 143, 291–294
  - ATP synthase, 106, 139
  - $\beta$ -barrels in outer membrane, 116, 165
  - cardiolipin (CL) synthesis, 39
  - cytochrome P450 enzymes, 136
  - F<sub>1</sub>F<sub>0</sub> ATP synthase, 379
  - inner membrane structure, 7–9
  - insertion of mitochondrial proteins, 193–195
  - membrane lipid production, 39
  - membrane phospholipids, 37
  - membranes, 1
  - PAM complex, 195
  - respiratory chain, 358–359
  - role of monoamine oxidase, 91
  - SAM complex, 191, 193, 194
  - TIM complexes, 193, 195
  - TOM complex, 193–194
  - VDACs (voltage-dependent anion channels), 122–123
- mitochondrial carrier family (MCF), 143, 285, 291–294
- mitochondrial processing peptidase (MPP), 195
- mitogens, 142
- model membrane systems, 51–52
- bicelles, 63
  - blebs, 64–65
  - blisters, 64–65
  - fluidity measurement, 9
  - giant unilamellar vesicles (GUVs), 62–63
  - large unilamellar vesicles (LUVs), 61–62
  - liposomes, 60–63
  - mixed micelles, 63
  - monolayers, 52–54
  - multilamellar vesicles (MLVs), 60–61
  - nanodiscs, 66–67
  - patch clamps, 57–58
  - planar bilayers, 54–56
  - proteoliposomes, 60, 61–62
  - short-chain/long-chain unilamellar vesicles (SLUVs), 62
  - small unilamellar vesicles (SUVs), 61
  - supported bilayers, 57–59
- modeling the bilayer
- molecular dynamics (MD) simulations, 209–213, 215
  - Monte Carlo simulations, 213–214
  - simulations of lipid bilayers, 209
- molecular dynamics (MD), 22
- calculations, 210
  - simulations, 209–213, 215
- molecular modeling
- structure of bilayer lipids, 24, 207, 209
- molybdopterin guanine dinucleotide (MGD), 240

## Index

- monoamine oxidase, 91  
 monoamines, 91  
 monolayers  
 model membrane systems, 52–54  
 monoolein, 31, 108  
 monopalmitolein, 108  
 monosaccharide headgroups, 21  
 monotopic proteins, 70, 91, 227  
 Montal–Mueller system, 55–57, 56  
 Monte Carlo simulations, 213–214  
 MPoPS (1-myristyl  
 2-palmitoleylphosphatidylserine), 6  
 MPTopo algorithm, 164  
 MscL channels, 349–350  
 MscS channels, 350–351  
 Multidisciplinary approach, 223, 390  
 multidrug efflux pumps, 316  
 multidrug resistance (MDR), 316,  
 320–325  
 cancer cells, 140  
 EmrD, 289–290  
 multilamellar vesicles (MLVs), 60–61  
 cytidyltransferase (CT) binding, 83  
 multiple sclerosis, 71, 270  
 myasthenic syndromes, 145  
 mycobacteria, 116, 165  
*Mycobacterium tuberculosis*, 349  
 myelin, 7, 39  
 myelin basic protein, 71, 77  
 myelin sheath, 71  
 myeloperoxidase family, 229  
 myristic acid, 15  
 1-myristyl  
 2-palmitoleylphosphatidylserine.  
*See* MPoPS
- Na<sup>+</sup> symport, 142  
 Na<sup>+</sup>,H<sup>+</sup> antiporter, 142  
 Na<sup>+</sup>-K<sup>+</sup> ATPase, 139, 250–254, 335  
 α-subunit, 250–251  
 β-subunit, 253  
 γ-subunit, 253  
 ion binding sites, 251–253  
 medical significance, 253–254  
 Na<sup>+</sup>, K<sup>+</sup> pump. *See* Na<sup>+</sup>, K<sup>+</sup> ATPase  
 NAD(P)H, 136  
 NADPH oxidase, 139  
 NaK channel, 337  
 nanodevices  
 gramicidin A, 90  
 nanodiscs  
 model membrane systems, 66–67  
 N-BAR domain, 83, 84  
 NBD-DLPE fluorescence probe, 31  
 NCS1 (nucleobase cation symporter)  
 family, 303  
 Neher, Erwin, 57  
*Neisseria gonorrhoeae*, 64  
 neonatal respiratory distress syndrome,  
 52  
 nerve membranes, 21  
 neural networks statistical method,  
 156–158  
 neurological disorders, 227, 253–254, 298  
 neuromuscular disorders, 145  
 neuronal synapses, 274, 294  
 neuropathy, 356  
 neurotransmitter receptors, 144, 145,  
 274–281  
 Cys-loop receptors, 278–281  
 GluA2 receptor, 274–278  
 GluCl receptor, 278–281  
 ionotropic receptors, 274  
 ligand-gated ion channels, 274  
 metabotropic receptors, 274  
 neurotransmitter transporters, 294–300  
 APC-fold superfamily, 300–303  
 drug targets, 294  
 EAATs family, 294–296  
 LeuT, 296–300  
 LeuT superfamily, 300–303  
 mode of action, 294  
 NSS family, 294, 296–300  
 prokaryotic orthologs, 294  
 neurotransmitters  
 inactivation, 91  
 neutron diffraction  
 detergents, 50–51  
 joint refinement of x-ray and neutron  
 diffraction data, 208  
 neutron scattering, 205–206  
 neutron scattering  
 structure of bilayer lipids, 223  
 NG (nonyl glucoside), 221  
 nicastrin (Nct), 135  
 Nicolson, G. L., 6–9, 34  
 nicotinamide adenine dinucleotide  
 (NAD<sup>+</sup>), 242  
 nicotinic acetylcholine receptor (nAChR),  
 278, 279  
 nigericin, 138  
 night blindness, 259  
 nitrate reductase, 239, 240, 358  
 nitrate respiratory pathway, 239, 358  
 NMDA (N-methyl-D-aspartate), 275  
 NMR. *See* nuclear magnetic resonance  
 non-bilayer-forming lipids  
 role in the membrane, 30  
 nonpolar domain, 1  
 noradrenaline, 267  
 norepinephrine, 294  
 reuptake inhibitors, 294  
 norepinephrine transporter, 298, 302  
 inhibitor, 294  
 NSAIDs (nonsteroidal anti-inflammatory  
 drugs), 227, 230  
 NSS (neurotransmitter: sodium  
 symporter) family, 294, 296–300  
 nuclear magnetic resonance (NMR), 223  
 cholesterol interactions with other  
 lipids, 22  
 DAGK structure, 133  
 determination of membrane protein  
 structures, 95–97  
*E. coli* membrane lipid diversity,  
 38–39  
 glycoporphin A, 95  
 SDS micelles, 46  
 structure of bilayer lipids, 23–24  
 structures of β-barrel membrane  
 proteins, 119–121  
 understanding conformational change,  
 390  
 use of bicelles, 63  
 use of micelles, 63  
 nuclear membrane, 1  
 nuclear Overhauser effect (NOE), 95,  
 119, 121  
 nuclear pore complex, 386–387  
 nucleobase cation symporter (NCS1)  
 family, 303  
 OCTOPUS program, 153  
 OG (octyl β-D-glucoside *also*  
 β-octylglucoside), 43, 45, 50, 51,  
 61, 221  
 osmoleic acid, 14, 15  
 oleoyl, 14  
 olfactory receptors, 145  
 oligomeric pore formation, 89  
 oligosaccharides, 21  
 omega-3 fatty acids, 15, 213  
 ω-sites, 76  
 OmpA, 121  
 protein folding studies, 175–177  
 OmpC porin, 117, 118–122  
 OmpF porin, 50, 55, 65, 117,  
 118–122  
 OmpG, 121  
 OMPLA (outer membrane phospholipase  
 A), 117, 165, 178, 230–234  
 OmpR, 121  
 OmpT, 234–235  
 OmpTins, 234–235  
 OmpX adhesion protein, 117, 119–121  
 OprM, 325  
 optical tweezers, 31  
 organophosphate: phosphate antiporter  
 family, 288  
 osmolytes, 298  
 O-succinyl ester, 132  
 ouabain, 253  
 outer membrane secretory proteins,  
 126–127  
 ovispirin, 89  
 P450 cytochromes. *See* cytochrome P450  
 enzymes  
 PA (phosphatidic acid), 19, 27, 132  
 PA (protective antigen), 86–88  
 PagP, 121  
 palmitic acid, 15  
 palmitoleic acid, 15

- 1-palmitoyl-2-oleoyl phosphatidylcholine.  
See POPC
- 1-palmitoyl-2-oleoyl  
phosphatidylglycerol. See POPG
- palmitoyl-sphingomyelin, 34
- PAM complex, 195
- Paracoccus denitrificans*, 366–367, 370
- paradigms, 3–4  
Fluid Mosaic Model, 3  
hydrophobic effect, 3  
implications of membrane rafts, 9  
shifting of the current paradigm, 4  
view for the future, 9–11
- Parkinson's disease, 298
- Parkinsonism, 254
- passive transport, 137–138
- Pasteurella haemolytica*, 325
- patch clamp technique, 348  
model membrane systems, 57–58
- PC (phosphatidylcholine), 17, 19, 27, 37, 46, 51, 62, 83, 102
- PE (phosphatidylethanolamine), 19, 27, 31, 37, 38–39, 62, 103, 112, 132
- PE (phosphatidylethanolamine)  
methylase, 37
- penicillin, 118
- penicillinase, 75
- PEP PTS transport system, 140–142
- peptides that insert into the membrane, 88–91
- peptidoglycan, 116
- peripheral proteins, 1, 6, 69–85
- permeability properties of membranes, 3
- pertussis toxin, 86
- PfAQP aquaporin, 334
- PG (phosphatidylglycerol), 19, 27, 37, 52, 132
- P-glycoprotein, 140, 316–318
- phage BF23, 313
- phase diagrams, 31–34  
ternary phase diagrams, 31–34
- phase transitions, fatty acid  
gel state, 17  
liquid crystalline state, 17
- phase transitions, lipids, 17  
in monolayers  
See also phase diagrams
- PHD neural networks algorithm, 153, 156–158
- Phi ( $\phi$ ) value analysis, 174
- Philius program, 154
- Phobius program, 153, 154
- PhoE (phosphoporin), 65, 117, 121, 123–124, 178
- phorbol esters, 74, 79, 81, 131
- phosphatases, 84
- phosphatidic acid. See PA
- phosphatidylcholine. See PC
- phosphatidylethanolamine. See PE
- phosphatidylglycerol. See PG
- phosphatidylinositol. See PI
- phosphatidylserine. See PS
- phosphocholine, 21, 83
- phosphoethanolamine, 21, 132
- phosphoglycerol, 132
- phosphoinositides, 82
- phospholamban, 92
- phospholipase A<sub>2</sub> (PLA<sub>2</sub>), 62, 71–72, 131–132
- phospholipase C, 62, 71, 74
- phospholipases, 19, 27, 71–72, 85
- phospholipids (PL), 11, 17–20
- photosynthetic reaction center, 109–115, 138  
antennae, 113–114  
cofactors, 112–113  
lipids, 112  
proteins, 110–112  
reaction cycle, 114–115
- PI (phosphatidylinositol), 19, 39
- PI3-kinase signaling pathways, 82
- picrotoxin, 279–281
- pid clamp of phospholipase A<sub>2</sub> (PLA<sub>2</sub>), 72
- plague, 230–234
- planar bilayers, 121  
black films, 54  
model membrane systems, 54–56
- plasma membrane, 1
- Plasmodium falciparum*, 334
- pleckstrin homology (PH) binding domain, 81–83
- pneumonia, 316
- polar clamp bonding pattern, 163
- polar headgroups, 1
- Polyphobius program, 154
- polyphosphorylated inositols, 85
- polystyrene beads, 50
- polytopic proteins, 69–70, 91
- polyunsaturated fatty acids, 15–17, 213
- POPC, 34, 177
- POPG, 177
- porins, 9, 117–124  
general porins, 117–123  
LamB (maltoporin), 124  
OmpC, 118–122  
OmpF, 118–122  
PhoE (phosphoporin), 123–124  
specific porins, 117, 123–124  
ScrY (sucrose-specific porin), 124  
VDACs, 122–123
- positive-inside rule for topology analysis, 150–151
- postranslational translocation, 180, 183
- potassium channels, 93, 335–343  
architecture, 335  
diversity of, 335  
gating and activation, 337–339  
gating in human potassium channels, 341–343  
K2P family, 341–343  
KcsA, 177–178, 329, 335–339  
MD simulations, 213
- structural studies, 335–336
- structure and selectivity, 336–337
- TRAAK, 341–343
- voltage gating, 339–341
- POX site, 228, 229
- predicting TM segments, 146–148
- PRED-TMBB algorithm, 164
- presenilin, 134–136
- presenilin enhancer-2 (Pen-2), 135
- prion proteins, 76, 200
- prokaryotes  
cell membrane arrangements, 1  
orthologs of brain neurotransmitter transporters, 294  
respiratory chain, 358–359  
sterols, 21  
transporters involved in drug efflux, 316
- proline, 93, 348
- proOmpA, 190
- propranolol, 267
- prostaglandin H<sub>2</sub> (PGH<sub>2</sub>), 227
- prostaglandin H<sub>2</sub> synthase (PGHS), 91, 227–230  
mechanism of action, 228
- prostaglandins, 15, 71, 145
- proteases, 102  
membrane proteases, 234–239
- proteasomes, 388
- Protein Data Bank (PDB), 146, 147
- protein folding studies, 168–178  
 $\alpha$ -helical membrane proteins, 170–173  
bacteriorhodopsin (bR), 172–173  
 $\beta$ -barrel membrane proteins, 175–177  
diacylglycerol kinase (DAGK), 177  
methodology, 169–170  
whole-protein hydrophobicity scale, 178  
See also folding of membrane proteins
- protein interactions with the membrane, 69  
amphitropic proteins, 70  
bitopic proteins, 69–70  
classes of interacting proteins, 69–70  
integral proteins, 69–70  
monotopic proteins, 70  
peripheral proteins, 69–70  
polytopic proteins, 69–70  
proteins at the bilayer surface, 70–85  
proteins embedded in the membrane, 91–103  
proteins that insert into the membrane, 85–91
- protein kinase C (PKC), 71, 74, 79–81, 131
- protein–lipid interactions, 4, 6
- protein misfolding diseases, 198–201
- protein–protein interactions, 4, 8
- protein-rich domains, 9
- proteinase K, 181
- proteinases, 140  
See also proteases

## Index

- proteins
- peripheral proteins, 70–85
  - polarity, 4
  - raft proteins, 36
- proteins at the bilayer surface, 70–85
- amphitropic proteins, 74
  - curvature of membranes, 83–84
  - domains involved in membrane binding, 81–83
  - effects of protein binding on membrane lipids, 778
  - interactions with membrane lipids, 78–81
  - lipid-anchored proteins, 75–77
  - membrane binding, 78–81
  - modulation of reversible binding, 84–85
  - reversible interactions with the lipid bilayer, 77
  - See also* protein–lipid interactions
- proteins embedded in the membrane, 91–103
- constraints on protein structure, 97–103
  - hydrophobic mismatch, 101–103
  - integral proteins, 91–95
  - monotopic proteins, 91
  - NMR determination of structures, 95–97
  - protein–lipid interactions, 97–103
- proteins that insert into the membrane, 85–91
- antimicrobial peptides, 88–89
  - colicins, 88
  - peptide ionophores, 89–90
  - SecA, 90–91
  - toxins, 86–88
- proteoliposomes, 60, 61–62, 121
- proteomics of membrane proteins, 163–164
- proton gradients. *See* respiratory chain complexes and secondary transporters
- proton motive force, 313–315, 375
- proton symport, 142
- Prozac (fluoxetine), 294
- PrP prion, 200
- PS (phosphatidylserine), 19, 27, 39, 131
- Pseudomonas aeruginosa*, 64, 320, 323, 325
- PSI-BLAST program, 147, 154
- PufX protein, 114
- puromycin, 102
- purple bacteria, 109
- purple membranes, 9, 105–109, 216
- Pyrococcus furiosus*, 189
- Pyrococcus horikoshii*, 294–296
- pyruvate, 143, 239
- Q cycle
- cytochrome *b<sub>cf</sub>*, 368
  - cytochrome *b<sub>c1</sub>*, 366
  - quinones, 112
- rafts. *See* lipid rafts; membrane rafts
- Ras GTPase superfamily, 75
- reactive oxygen species, 366
- recoverin, 85
- redox loop, 240–242
- redox proteins, 139
- renal disease, 253
- respirasomes, 358
- respiratory chain
- in prokaryotic membranes, 358–359
  - mitochondrial respiratory chain, 358–359
  - size and complexity of components, 358
- respiratory chain complexes, 359–383
- complex I, 359–365
  - complex II, 359
  - complex III (cytochrome *b<sub>c1</sub>*), 359, 365–370
  - complex IV (cytochrome *c* oxidase), 359, 371–375
  - complex V (*F<sub>1</sub>F<sub>0</sub>* ATP synthase), 375–383
- respiratory distress, 289
- respiratory distress syndrome
- premature babies, 52
- retinal, 106, 107, 173
- 11-*cis* retinal, 266
- retinal analogs, 108
- retinal disease, 201
- retinitis pigmentosa, 200–201
- Rhodobacter capsulatus*, 116, 121, 151, 366
- Rhodobacter sphaeroides*
- (*Rhodospseudomonas sphaeroides*), 37, 109, 112, 115, 216, 366, 370, 374
- Rhodospseudomonas viridis* (*Blastochloris viridis*), 109, 110–112, 113
- rhodopsin, 75, 102, 106, 107, 163, 213, 258, 259–266
- activated state, 261–263
  - as GPCR prototype, 263–266
  - ground state, 260–261
  - light-induced signal transduction efficiency, 260
- rhodopsin family of GPCRs, 259, 264
- rhomboid proteases, 134, 236–239
- structure of bacterial GlpG, 237–239
- ribitol, 330
- ribonuclease (RNase), 102
- ribose, 142
- ribosomes, 180, 187
- RND superfamily, 190, 316
- RnfA protein, 151
- RnfE protein, 151
- rofecoxib (Vioxx), 227
- ROSETTA protein-folding algorithm, 154–155
- Rossmann fold, 245, 311
- rotational catalysis, 380–383
- rotational diffusion of bilayer lipids, 24
- Saccharomyces cerevisiae*, 363
- Sakmann, Bert, 57
- salbutamol, 267, 268, 270
- salt bridges, 287, 293
- SAM complex, 191, 193, 194
- saponins, 43, 76
- sarcoplasmic reticulum, 92, 93, 244
- sarcoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase. *See* SERCA
- Sav1866, 140, 316–318
- SCAMPI algorithm, 154
- SCC (sodium: solute symporter) family, 303
- schizophrenia, 294
- scissile bonds, 234, 235
- SCOP database, 147
- ScrY (sucrose porin), 117
- SDS (sodium dodecylsulfate), 43, 45, 46, 47, 50, 96, 173
- SDS-PAGE, 177, 180, 181
- SDSL (site-directed spin labeling), 99
- sea anemones
- toxins, 88
- Sec61 translocon, 187
- SecA, 37, 90–91, 187, 189
- SecB, 183
- SecDF heterodimer, 187, 190
- SecE, 187, 189
- SecG, 187
- second messengers, 20, 71, 145, 257, 258
- secondary transporters, 284–291
- EmrD, 289–290
  - first views of, 285
  - FucP (fucose/ $\text{H}^{+}$  symporter), 290–291
  - GlpT antiporter, 288–289
  - lactose permease (LacY protein), 285–287
  - paradigm for MFS transporters, 291
- $\beta$ -secretase (BACE1), 135
- $\gamma$ -secretase, 135–136, 236
- secretin family of GPCRs, 259
- secretory vesicles, 139
- SecY, 187, 189
- SecYE, 189
- SecYEG translocon, 66, 164
- sedatives, 328
- seizures, 289
- senile plaques, 134
- sensory rhodopsin II, 162
- sequence alignment, 155
- SERCA
- ATP binding and hydrolysis, 247–249
  - $\text{Ca}^{2+}$  binding sites, 246–247
  - conformational changes, 249–250
  - cytoplasmic domains, 245
  - TM domains, 246
- serine proteases, 235–236

- serine zipper motif, 163  
serotonin, 91, 258, 294  
  reuptake inhibitors, 294  
serotonin 5-HT<sub>3</sub> receptor, 279  
serotonin transporter, 294, 298, 302  
  inhibitor, 294  
*Serratia marcescens*, 126  
Shaker channels, 336  
short-chain/long-chain unilamellar  
  vesicles (SLUVs), 62  
sialic acid, 76  
siderophores, 125  
signal peptidase, 181, 191  
signal peptide peptidase (SPP), 134, 236  
signal peptides, 153  
signal recognition particles (SRPs),  
  180–183  
signal transduction  
  light induced, 260  
signal transduction pathways, 257, 258  
signaling, 354  
signaling complexes, 76  
signaling molecules, 257, 258  
signaling pathways, 84  
signaling proteins, 36  
SignalP program, 153  
SignalP-HMM program, 153  
simulations, 203  
  approaches to the lipid bilayer,  
  203–204  
  combined experimental and  
  computational approaches, 204  
  computer modeling, 209–213  
  lipid bilayer simulations, 209  
  molecular dynamics (MD) simulations,  
  209–213, 215  
  Monte Carlo simulations, 213–214  
  multidisciplinary approach, 223  
Singer, S. J., 6–9, 34  
single-particle tracking, 9, 25, 31  
site-directed spin labeling (SDSL), 99  
site protease 2 (SP2), 134  
sitosterol, 21  
skin disorders, 356  
Skou, Jens C., 250  
SLC1 (solute carrier 1) family, 296  
SLC6 (solute carrier 6) family, 301  
SM<sub>2</sub> Bio-Beads, 50  
small GTPases, 75  
small unilamellar vesicles (SUVs), 61  
SMR (small MDR) family, 316  
SNARE proteins, 387–388  
snorkeling of polar groups, 93  
S<sub>0</sub> state, 31–34  
sodium cholate, 43, 45, 46, 50, 61  
sodium deoxycholate, 43, 50  
sodium dodecylsulfate. *See* SDS  
sodium–potassium pump. *See* Na<sup>+</sup>, K<sup>+</sup>  
  ATPase  
sodium: solute symporter (SCC) family,  
  303  
solute carrier 1 (SLC1) family, 296  
solute carrier 6 (SLC6) family, 301  
SOPC, 212  
spectrin, 71  
sphingolipids, 1, 9, 17–19, 20–21  
sphingomyelin, 21, 27, 62, 132  
sphingophospholipids, 17–19, 21  
sphingosine 1-phosphate receptor I  
  (S1pI), 270  
spider toxins, 88  
spin probes, 99  
SPOCTOPUS program, 153, 154  
squalene-hopene cyclase, 91  
Src family, 36, 75  
Src peptide, 79, 84  
*Staphylococcus aureus*, 86, 140, 316  
statistical methods for TM prediction,  
  156–160  
  hidden Markov models, 158–160  
  neural networks, 156–158  
stearic acid, 14, 15  
1-stearol-2-oleoyl phosphatidylcholine.  
  *See* SOPC  
stearyl, 14  
Stephen White laboratory, 91  
steroids, 21  
  biosynthesis, 67  
sterols, 1, 17–19, 21–22  
stigmaterol, 21  
stigmatellin, 370  
stop transfer sequences, 191  
*Streptomyces lividans*, 335  
stroke, 294, 334  
structural repeats in transporters,  
  151–153  
study of membrane components  
  detergents, 43–51  
  purification challenges, 42–43  
  purification process, 43  
  range of tools and techniques, 42–43  
succinate dehydrogenase, 164  
sucrose, 124  
sugars  
  families of uptake systems, 139  
  group translocation, 140–142  
supported bilayers  
  model membrane systems, 57–59  
surface dilution effects, 131–132  
surface tension, 43  
surfactants, 20, 43  
  pulmonary surfactant, 52  
Swiss-Prot protein sequence databank,  
  146, 147, 155, 160  
symport  
  definition, 137  
symporters, 142  
  FucP (fucose/H<sup>+</sup> symporter), 290–291  
  LacY (lactose/H<sup>+</sup> symporter), 285–287  
Tanford's partitioning data for fatty  
  acids, 78  
TAP (transporter for antigen processing),  
  140, 388  
tapasin, 388  
taurine, 298  
Tay-Sachs disease, 17–19  
TBDTs (TonB-dependent transporters),  
  31, 315  
TDG ( $\beta$ -D-galactopyranosyl 1-thio- $\beta$ -D-  
  galactopyranoside), 286  
terpenes, 75  
tetanus neurotoxin, 86  
tetracycline, 318  
tetraphenylphosphonium (TPP<sup>+</sup>), 318  
*Thermochromatium tepidum*, 109, 112,  
  115, 217, 218  
thermodynamics  
   $\alpha$ -helix protein folding and insertion,  
  170, 172  
  hydrophobic effect, 4–5  
  lipid structural polymorphism, 30  
  membrane formation, 4–5  
*Thermotoga maritima*, 189  
*Thermus thermophilus*, 190, 359–363  
thioesterase, 85  
thrombosis, 227  
thromboxanes, 71  
tight junctions, 39  
TIM complexes, 193, 195  
timolol, 268  
TMBETAPRED-RBF algorithm, 164  
TMB-HMM algorithm, 164  
TMBpro algorithm, 164  
TMHMM algorithm, 153, 154, 158–160  
Tol system, 88  
TolC, 126, 316, 320–325  
  partners of TolC, 325  
TOM complex, 193–194  
Ton system, 88  
TonB, 125, 126  
TonB box, 125  
TonB-dependent transporters (TBDTs),  
  313–315  
TonB/ExbB/ExbD complex, 310, 313–315  
TonB family, 138  
TOPCONS algorithm, 153–154  
topogenesis in membrane proteins,  
  195–198  
topoisomerases, 37  
TOPPED algorithm, 151, 153  
toroidal pore formation, 89  
*Torpedo* electric ray, 343  
torsion angle, 15  
toxins, 138, 140  
  peptides that insert into the  
  membrane, 88  
  proteins that insert into the  
  membrane, 86–88  
TRAAK potassium channel, 336, 341–343  
TRAM protein, 190  
*trans* fatty acids, 14  
*trans* torsion angle, 15

## Index

- transducin, 260, 266  
transferrin receptor, 75  
*trans-gauche* isomerism, 98, 99  
transient membrane complexes, 387–388, 390  
translocon, 179, 187  
  structure, 187–189  
transmembrane (TM) segments, 1  
  *See also* predicting TM segments  
transmembrane potential  
  Na<sup>+</sup>-K<sup>+</sup> pump, 139  
transport classification system, 138–139  
transport proteins  
  ABC transporters, 306–313  
  APC-fold superfamily, 300–303  
  BetP, 303–306  
  BtuB, 313–315  
  BtuCD-BtuF transporter, 311–313  
  diversity of, 284  
  drug efflux systems, 316–325  
  EmrD, 289–290  
  EmrE, 318–320  
  FucP (fucose/H<sup>+</sup> symporter), 290–291  
  GlpT antiporter, 288–289  
  GltPh, 294–296  
  glutamate transporters, 294–296  
  lactose permease (LacY protein), 285–287  
  LeuT, 296–300  
  LeuT superfamily, 300–303  
  major facilitator superfamily (MFS), 284–291  
  maltose transporter, 306–310  
  mitochondrial ADP/ATP carrier (AAC), 291–294  
  neurotransmitter transporters, 294–300  
  NSS family, 296–300  
  P-glycoprotein, 316–318  
  Sav1866, 316–318  
  secondary transporters, 284–291  
  structure–function relationships, 284  
  TonB/ExbB/ExbD complex, 313–315  
  TonB-dependent transporters (TBDTs), 313–315  
  vitamin B<sub>12</sub> uptake system, 310–315  
  *See also* membrane transport proteins  
transverse diffusion of bilayer lipids, 24, 25–27  
traumatic head injury, 334  
tricyclic antidepressants, 302  
trigger factor (TF), 191  
trinitrobenzenesulfonic acid (TNBS), 27  
tripod amphiphiles, 45  
Triton X-100, 35–36, 43, 50, 63, 131, 178  
Trojan peptides, 88  
TROSY, 95, 119, 121  
Tsx (nucleoside channel), 117, 124–125  
tuberculosis, 316  
tumors  
  brain, 334  
  expression of annexins, 74  
  formation, 79  
  multidrug resistance, 316  
twin arginine translocation (TAT)  
  pathway, 191  
tyrosine kinases, 36, 75, 76  
ubiquinol (ubihydroquinone), 366  
ubiquinol-cytochrome *c* reductase, 365  
ubiquinol oxidase, 164  
ubiquinone, 112  
undecaprenol kinase (UDPK), 133  
uniport  
  definition, 137  
urinary tract infections, 288  
vacuoles in plant cells, 139  
valine, 95  
valinomycin, 138  
van der Waals forces, 17, 95, 172, 288  
VceC, 325  
VDACs (voltage-dependent anion channels), 121, 122–123  
*Vibrio cholerae*, 325  
video fluorescence microscopy, 25  
vinculin, 83  
viral envelope formation, 36  
virulence of bacteria, 232, 234  
viruses  
  membrane envelopes, 1  
  vitamin B<sub>12</sub> receptor, 125  
  vitamin B<sub>12</sub> transporter, 140  
  vitamin B<sub>12</sub> uptake system, 310–315  
voltage-dependent anion channels (VDACs), 121, 122–123  
voltage-gated potassium channels, 339–341  
voltage-sensitive potassium channels, 335  
von Heijne positive-inside rule, 150–151  
Walker, John E., 376  
water  
  hydrogen bonding, 4–5  
water channels. *See* aquaporins  
whole-protein hydrophobicity scale, 178  
Wilson's disease, 255  
Wimley–White (WW) scale, 148  
Wuthrich, Kurt, 95  
Wza ( $\alpha$ -helical barrel), 126–127  
*Xenopus* oocytes, 64, 279  
x-ray crystallography, 203–204, 205  
  bacteriorhodopsin, 108  
  cholesterol, 21  
  lamellar phase PLs, 28  
  limitations for understanding  
  conformational change, 390  
  structure of lipids, 22  
  integral membrane proteins, 91  
  use in bioinformatics, 147  
x-ray diffraction, 204  
  crystallography of membrane  
  proteins, 219–223  
  joint refinement of x-ray and neutron  
  diffraction data, 208  
  x-ray scattering, 205–206  
x-ray scattering, 205–206  
  membrane thickness, 102–103  
  structure of bilayer lipids, 223  
x-ray structures of membrane proteins  
  lipids in, 215–216  
*Yarrowia lipolytica*, 363  
yeast  
  chaperone proteins, 182  
  cytochrome P450 structure, 137  
  cytochrome *bc*<sub>1</sub> complex, 216, 370  
  ergosterol, 21  
  MscS channels, 350  
  respiratory chain, 363  
  translocon, 187  
  two-hybrid analysis, 164  
*Yersinia pestis*, 234, 235  
YidC protein, 187, 190  
ZPRED algorithm, 165  
zwitterions  
  detergents, 43  
  lipids, 38  
  phospholipids (PLs), 19